Daiichi Sankyo and Merck report phase 2 trial results for lung cancer drug
John Wiley & Sons A stock recently reached a 52-week low, hitting a price of 36.27 USD. This decline marks a significant point for the company, as it reflects a downturn over the past year. The stock has experienced a 13.75% decrease in value over the past 12 months, amid a 10.4% revenue decline. However, InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US stocks.
In other recent news, John Wiley & Sons, Inc. reported first-quarter adjusted earnings per share of $0.49, surpassing analyst expectations of $0.32. The company’s revenue reached $397 million, exceeding the consensus estimate of $375 million. Despite a slight decline in total revenue from $404 million a year earlier, adjusted revenue saw a 1% increase at constant currency. The company maintained its full-year guidance, emphasizing its commitment to expanding AI licensing initiatives. Research revenue, Wiley’s largest segment, experienced a 5% growth at constant currency, reaching $282 million. This growth was significantly driven by $16 million in AI licensing revenue, a notable increase from $1 million in the prior-year period. These developments highlight the company’s strategic focus on AI and its impact on revenue streams.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.